OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Intracerebral haemorrhage (bleeding in the brain), also known as haemorrhagic stroke, leads to approximately 3 million deaths worldwide per year and leaves many survivors disabled and dependent on others. It is possible that administering medications to stop bleeding quickly after the onset of intracerebral haemorrhage might reduce the risk of people dying or becoming disabled. This talk will outline pre-clinical work assessing the role of Von Willebrand factor for reversing or reducing the effects of antiplatelet drugs (these are prescribed in patients who are at risk of heart attacks or blood clots, but they increase the risks from intracerebral haemorrhage) and discuss ongoing clinical trials of tranexamic acid and desmopressin aimed at reducing bleeding. It will also discuss research into newborn babies with a condition called Fetal and Neonatal AlloImmune Thrombocytopenia (FNAIT), who are at risk of intracerebral haemorrhage in the womb or shortly after birth.
